Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742800 | 1.00 | DPP4 (0.41) | DPP4HDAC1HDAC8RORCSMN1; SMN2 | |
| SCHEMBL29738305 | 1.00 | DPP4 (0.41) | DPP4HDAC1HDAC8RORCSMN1; SMN2 | |
| SCHEMBL440648 | 0.85 | NPSR1 (0.38) | DPP4RORCDPP9MMP1MMP2 | |
| SCHEMBL409968 | 0.85 | NPSR1 (0.38) | DPP4RORCDPP9MMP1MMP2 | |
| SCHEMBL30607053 | 0.85 | NPSR1 (0.38) | DPP4RORCDPP9MMP1MMP2 | |
| SCHEMBL13780810 | 0.82 | DPP4 (0.36) | DPP4HDAC1HDAC8RORCCYP2D6 | |
| SCHEMBL3801146 | 0.81 | MAPT (0.39) | DPP4MMP1MMP2MMP9MMP12 | |
| SCHEMBL3801151 | 0.81 | MAPT (0.39) | DPP4MMP1MMP2MMP9MMP12 | |
| SCHEMBL18752139 | 0.80 | ATM (0.41) | SMN1; SMN2PDE4D | |
| SCHEMBL749408 | 0.80 | HDAC1 (0.35) | DPP4HDAC1HDAC8RORCDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112225666-B | Preparation method of (R) -3-amino-4- (2,4, 5-trifluorophenyl) methyl butyrate | 江苏八巨药业有限公司 | 2022-04-19 | — | — | CN | claimed |
| CN-112225666-A | Preparation method of (R) -3-amino-4- (2,4, 5-trifluorophenyl) methyl butyrate | 江苏八巨药业有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-110759914-A | Preparation method of medicine for treating diabetes | 美华东进国际生物医药研究院有限公司 | 2020-02-07 | — | — | CN | claimed |
| CN-115960007-B | Preparation method of sitagliptin intermediate by using nitrogen-containing formyl catalyst | 浙江大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-115819258-B | Preparation method of sitagliptin intermediate by using catalyst containing phosphine-oxygen double bond | 浙江大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-112341332-B | Recycling method of sitagliptin key intermediate degradation waste | 浙江昌明药业有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-115960007-A | Preparation method of sitagliptin intermediate by using nitrogen-containing formyl catalyst | 浙江大学 | 2023-04-14 | — | — | CN | disclosed |
| CN-115819258-A | Preparation method of sitagliptin intermediate by using phosphine-oxygen double bond-containing catalyst | 浙江大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-112225666-B | Preparation method of (R) -3-amino-4- (2,4, 5-trifluorophenyl) methyl butyrate | 江苏八巨药业有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-112225666-B | Preparation method of (R) -3-amino-4- (2,4, 5-trifluorophenyl) methyl butyrate | 江苏八巨药业有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-112341332-A | Recycling method of sitagliptin key intermediate degradation waste | 浙江昌明药业有限公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-112225666-A | Preparation method of (R) -3-amino-4- (2,4, 5-trifluorophenyl) methyl butyrate | 江苏八巨药业有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-112225666-A | Preparation method of (R) -3-amino-4- (2,4, 5-trifluorophenyl) methyl butyrate | 江苏八巨药业有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-110759914-A | Preparation method of medicine for treating diabetes | 美华东进国际生物医药研究院有限公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-2381772-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8278486-B2 | Process and intermediates for the preparation of N-acylated-4-aryl beta-amino acid derivatives | CHIRAL QUEST, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | CHIRAL QUEST, INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280245-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF N-ACYLATED-4-ARYL BETA-AMINO ACID DERIVATIVES | NR4A3, GRIA3, NR2C2 | DPP4 3380/4885HDAC1 601/4885HDAC8 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.